Prosecution Insights
Last updated: May 29, 2026

Sigilon Therapeutics Inc.

6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
2
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (67%)
1
Easy (17%)
1
Unknown (17%)

Rejection Statute Mix

BucketCases
§103 only4 (67%)
§112 only1 (17%)
No statute on record1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ZAHORIK, AMANDA MARY 1 60.9% +52.6%
CHANDRAKUMAR, NIZAL S 1 72.6% +18.2%
GZYBOWSKI, MICHAEL STANLEY 1 67.6% +54.3%
WILSON, MICHAEL C 1 41.7% +17.6%
BEANE, RANDALL L 1 32.5% +37.8%
BABSON, NICOLE PLOURDE 1 46.5% +32.0%

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
17598154 COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY WILSON, MICHAEL C 215d overdue
17280802 IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS BEANE, RANDALL L 30d overdue
17784972 COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF CHANDRAKUMAR, NIZAL S 29d overdue
17045137 METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS BABSON, NICOLE PLOURDE 23d overdue
18276010 COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE ZAHORIK, AMANDA MARY 5d overdue
17764096 METHODS OF EVALUATING POLYPEPTIDE-MODIFIED POLYMERS IN COMPOSITIONS GZYBOWSKI, MICHAEL STANLEY 9d

Top Art Units

Art UnitApps
1636 1
1625 1
1798 1
1638 1
1654 1
1619 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18276010 COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE ZAHORIK, AMANDA MARY 1636 §103 Non-Final OA 5d overdue Pending Aug 04, 2023
17784972 COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF CHANDRAKUMAR, NIZAL S 1625 Other Non-Final OA 29d overdue Pending Jun 13, 2022
17764096 METHODS OF EVALUATING POLYPEPTIDE-MODIFIED POLYMERS IN COMPOSITIONS GZYBOWSKI, MICHAEL STANLEY 1798 §103 Non-Final OA 9d Pending Mar 25, 2022
17598154 COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY WILSON, MICHAEL C 1638 §103 Non-Final OA 215d overdue Pending Sep 24, 2021
17280802 IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS BEANE, RANDALL L 1654 §112 Final Rejection 30d overdue Pending Mar 26, 2021
17045137 METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS BABSON, NICOLE PLOURDE 1619 §103 Final Rejection 23d overdue Pending Oct 02, 2020

Managing Sigilon Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month